Mandibular Advancement Devices: Evidence‑Based Guidelines for Obstructive Sleep Apnea

1. Treatment Indications & Patient Selection

• Custom, titratable mandibular advancement devices (MADs) are recommended as first‑line therapy for patients with mild‑to‑moderate OSA (AHI < 30) who have no significant comorbidities and as the preferred alternative for any CPAP‑intolerant patient, regardless of OSA severity. [1][2]
• Primary clinical indications for MAD therapy include:
  
  • Mild‑to‑moderate OSA without cardiovascular comorbidities (first‑line). [1][2]
  • CPAP intolerance (any severity, including very severe disease with AHI ≥ 50). 1
  • Primary snoring without obstructive events. [1][2]

2. Predictors of Therapeutic Success

• Higher likelihood of MAD success is associated with younger age, female sex, lower body‑mass index, smaller neck circumference, position‑dependent OSA, and lower baseline AHI. 3

3. Multidisciplinary Care Model

• Qualified dentists with specialized training in dental sleep medicine must be integral members of the sleep‑medicine team, not merely consultants. [1][2]4
• Dentist responsibilities:
  
  • Screen for sleep‑disordered breathing during routine dental visits to reduce under‑diagnosis. [1][2]
  • Order sleep studies to confirm treatment efficacy and guide MAD titration. [1][5]
  • Fabricate and titrate custom MADs using incremental adjustments of ≤ 1 mm across a total protrusive range of ≥ 5 mm. [5][3]
• Sleep‑physician responsibilities:
  
  • Confirm OSA diagnosis before initiating MAD therapy. [1][4]
  • Verify treatment success with objective sleep testing while the MAD is in place. [5][3]
  • Monitor cardiovascular and metabolic comorbidities throughout therapy. [1][4]
• This model represents a mandatory collaborative care approach between sleep physicians and dental sleep specialists. [1][4]

4. Device Specifications & Titration Protocol

• Only custom‑made, titratable, dual‑block MADs that engage both maxillary and mandibular arches should be prescribed; prefabricated or non‑titratable devices are not recommended. 3
• Essential device characteristics:
  
  • Biocompatible materials with stable retention to teeth, implants, or edentulous ridges. 3
  • Incremental advancement capability of ≤ 1 mm per step with a minimum total protrusive range of 5 mm. [5][3]
  • Reversible adjustment mechanism to allow reduction if side effects occur. 3
  • Dual‑arch engagement to maintain the prescribed mandibular position during sleep. 3
• Titration strategy: Begin at ~50 % of the maximum protrusion and advance incrementally based on symptom response and objective sleep testing; “trial‑and‑error” remains the standard due to the cost of in‑laboratory titration, per 2025 Portuguese guidelines. 5
• Emerging evidence suggests that sleep‑endoscopy‑guided titration may further improve outcomes. [5][3]

5. Objective Verification of Treatment Efficacy

• Symptom improvement alone is insufficient; a follow‑up sleep study with the MAD in situ is mandatory to confirm adequate AHI reduction. 5
• Testing protocol:
  
  • Type 3 portable monitoring (home sleep apnea testing) is acceptable and cost‑effective for verifying MAD efficacy. 5
  • Testing must be performed with the MAD in place after final titration. [5][3]
  • Results should be compared to the baseline diagnostic study to quantify treatment response. 5

6. Evidence Hierarchy

• The 2011 European Respiratory Society (ERS) guidelines assign the highest level of evidence (13 randomized controlled trials) to MADs among all non‑CPAP therapies for OSA. 6

7. Clinical Pitfalls & Risk Mitigation

• Dental suitability must be confirmed before MAD fabrication; this includes adequate dentition, healthy periodontium, and absence of active temporomandibular disorders. [5][3]
• Initial side effects (jaw discomfort, tooth tenderness, excess salivation) are usually mild and transient; the reversible nature of MAD advancement allows reduction if side effects become intolerable. 3

8. Integration with Other Therapeutic Modalities

• Treatment hierarchy for CPAP‑intolerant patients:
  
  • Mild‑to‑moderate OSA (AHI < 30) – custom titratable MAD as the first alternative. 1
  • Moderate‑to‑severe OSA (AHI ≥ 30) – custom titratable MAD (recognizing less complete AHI normalization) followed, when appropriate, by hypoglossal nerve stimulation (BMI < 32 kg/m², AHI 15‑65) or maxillomandibular advancement (MMA) as salvage therapy. 6

9. Economic & Healthcare System Implications

• Successful integration of MAD therapy requires reimbursement structures for dental sleep‑medicine services and credentialing standards for qualified dentists. [1][2]
• Dental screening programs can markedly reduce OSA under‑diagnosis, delivering substantial social and economic benefits. [1][2]
• A system‑wide focus on prevention and early diagnosis is essential to lessen the economic and societal burden of untreated sleep‑disordered breathing. [1][2]

10. Research Gaps & Future Directions

• Cost‑effectiveness analyses comparing in‑laboratory titration protocols with empirical (“trial‑and‑error”) adjustment are needed. [5][3]
• Additional studies should evaluate long‑term cardiovascular outcomes of MAD therapy versus CPAP, and refine predictive models for treatment response beyond current demographic factors.

Role of Mandibular Advancement Devices in Treating Obstructive Sleep Apnea

Effectiveness of MADs in OSA

• The American Thoracic Society recommends mandibular advancement devices (MADs) as first-line therapy for patients with mild to moderate obstructive sleep apnea (OSA) and as an alternative therapy for patients with severe OSA who are intolerant to or refuse CPAP therapy, with treatment success rates and improvement in quality of life measures 7, 8
• MADs reduce the apnea-hypopnea index (AHI), arousal index, and daytime sleepiness while improving quality of life measures in adult patients with OSA, with approximately 52% overall treatment success rate 8, 9
• Although CPAP is superior to MADs in normalizing respiratory parameters, both treatments demonstrate comparable effects on symptoms and health-related quality of life measures 8

Patient Selection Criteria

• Ideal candidates for MAD therapy include patients with mild to moderate OSA with no comorbidities, patients with severe OSA who are intolerant to CPAP or request an alternative therapy, and patients with primary snoring, according to the American Academy of Sleep Medicine 7, 8, 9
• Factors associated with better treatment success include younger age, female gender, lower BMI, smaller neck circumference, position-dependent OSA, and lower baseline AHI, as recommended by the American College of Chest Physicians 8, 10

Device Characteristics and Implementation

• An effective MAD should be individualized and titratable, made of biocompatible materials, engage both maxillary and mandibular arches, be stable and retentive to teeth or implants, and capable of advancing the mandible in increments of 1mm or less, as specified by the European Respiratory Society 8, 11
• The recommended protocol includes initial titration starting at approximately 50% of maximum mandibular advancement, with custom-made devices being more effective than prefabricated ones, and follow-up sleep testing to verify treatment efficacy, according to the European Respiratory Journal 10

Adherence and Patient Preference

• Adherence with MADs is typically better than with CPAP in OSA patients, with high patient satisfaction, as reported by the American Academy of Sleep Medicine 8, 9

Potential Side Effects and Monitoring

• Initial side effects of MADs are common but generally minor and transient, including jaw discomfort, tooth tenderness, and excessive salivation, as noted by the European Respiratory Journal 10
• Regular follow-up is recommended to monitor treatment efficacy and potential side effects, such as temporary occlusal changes, as advised by the European Respiratory Society 10

Clinical Pitfalls and Considerations

• A multidisciplinary approach involving sleep physicians and qualified dentists is essential for optimal patient outcomes, as recommended by the American College of Chest Physicians 8, 9
• Re-evaluation with sleep testing is necessary after MAD titration, as improvement in symptoms alone is an imprecise indicator of treatment success, according to the European Respiratory Journal 10